Nirvana Life Sciences Inc. reported earnings results for the third quarter and nine months ended January 31, 2024. For the third quarter, the company reported net income was CAD 0.005374 million compared to net loss of CAD 0.23414 million a year ago.
For the nine months, net loss was CAD 0.523995 million compared to CAD 0.783157 million a year ago. Basic loss per share from continuing operations was CAD 0.01 compared to CAD 0.02 a year ago.